Insight Molecular Diagnostics Inc. — Director's Dealing 2017

Jun 20, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2017-06-15

Reporting Person: Last Andrew J. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-15	Option to Purchase Common Stock	$5.10	A	6520	Acquired	2027-06-14	Common Stock (6520)	Direct
2017-06-15	Option to Purchase Common Stock	$5.10	A	20000	Acquired	2027-06-14	Common Stock (20000)	Direct

Footnotes

F1: Options are granted to directors annually. These options are a "transitional grant" reflecting the change in the date of the annual grant from February to the date of the annual meeting of shareholders. The options are 32.60% of the annual grant for the 119-day gap between February 16, 2017, one year from the last annual grant, and June 15, 2017, date of the full annual grant for 2017-2018.

F2: Will become exercisable in four equal installments on September 30, 2017, December 31, 2017, March 31, 2018, and one day before the Company's next annual meeting of shareholders, based upon continued service on the board of directors from the date of grant on June 15, 2017.